02946: Towards Curative Outcomes in Canine Hemangiosarcoma

Grant Status: Open

Grant Amount: $348,559
Chand Khanna, DVM, PhD; Ethos Discovery
November 1, 2021 - October 31, 2026

Sponsor(s): American Wirehaired Pointing Griffon Foundation, Australian Shepherd Health & Genetics Institute, Dalmatian Club of America Foundation, Inc., Great Dane Club of America, Irish Setter Club of America Foundation, National Beagle Club, United States Australian Shepherd Foundation, Westie Foundation of America, Inc.

Breed(s): -All Dogs
Research Program Area: Oncology - Hemangiosarcoma
Donate to Support this Research Program Area

One Health: Yes


Canine hemangiosarcoma is the most aggressive cancer seen in all dogs, but disproportionately affects older, large breed dogs. Despite aggressive treatment with surgery and chemotherapy, more than 50% of dogs die due to metastatic spread of their cancer within 6 months and no significant advancements in the treatment of hemangiosarcoma have occurred in over 30 years. Several challenges have hindered improvements in outcomes including limitations in the capabilities of current imaging and/or blood-based markers to detect early relapse/metastasis, gaps in current understanding of the molecular biology of hemangiosarcoma, and a lack of effective therapies that effectively alter the aggressive metastatic behavior of this cancer. A nation-wide clinical trial for 400 dogs with splenic hemangiosarcoma seeks to deliver curative outcomes for dogs with this disease. With collaboration from AKC Canine Health Foundation, dog-owning families from outside the geographical enactment of 30 Ethos veterinary hospitals can join the trial to receive care, and to conduct genomic correlative studies with two internationally recognized scientific teams to gain critical new knowledge necessary to propel the field to this future goal of curative outcomes. Researchers will utilize a patient-forward approach and leverage genomic insight into hemangiosarcoma to propose and answer the following questions: (1) are there molecular biomarkers that predict prognosis in dogs with this disease?; (2) can we define genomic subgroups of dogs with hemangiosarcoma who are most likely to benefit from specific anticancer drugs?; (3) can we define new therapeutic approaches to prevent the spread of this cancer? This approach follows the road map used in transforming childhood leukemia from a fatal diagnosis to a commonly cured disease. By leveraging the strengths of a unique and multidisciplinary team of clinicians and scientists, this canine hemangiosarcoma study will lay the foundation for accelerating drug development and improving patient outcomes for dogs with this devastating disease.

Learn how you can participate in this research!


None at this time.

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Get Canine Health News:
Please leave this field empty
American Kennel Club Canine Health Foundation, Inc

8051 Arco Corporate Dr.
Suite 300
Raleigh, NC 27617

Tax ID# 13-3813813


© 2021 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.